The collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trialTORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced a strategic research collaboration with Fondazion ...

As Filed with the Securities and Exchange Commission on March 23, 2026. Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIAI HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION 17304 Preston Road, Suite 520 Dallas, TX 75252 (214) 935-9853 (Address, including zip code, and telephone number, including area co ...

Core Insights - NetraMark Holdings Inc. has demonstrated the potential of its explainable AI platform, NetraAI, to identify clinically meaningful responder subgroups in the A4 trial for Alzheimer's disease, which could enhance precision medicine strategies in future clinical trials [1][4][10] Group 1: Findings from the A4 Trial - The A4 trial initially showed no significant overall benefit for solanezumab, but NetraAI identified two distinct patient subgroups with meaningful treatment effects compared to placebo [4][7] - Key characteristics of these subgroups include higher regional brain volume and stronger baseline cognitive performance, with effect sizes reaching Cohen's d up to 1.52 [7] Group 2: Implications for Drug Development - The findings highlight the challenge of patient heterogeneity in Alzheimer's clinical trials, which can obscure meaningful drug responses [5][10] - NetraAI's ability to define subgroups based on a small number of baseline variables could support precision enrichment strategies, improving trial design and potentially reducing development risks and costs [8][9] Group 3: Technological Advancements - NetraAI employs a unique methodology that separates small datasets into explainable and unexplainable subsets, enhancing the likelihood of clinical trial success by avoiding overfitting [11] - The technology aligns with the industry's shift towards understanding which patients are most likely to benefit from therapies, thereby reshaping clinical trial designs [10][12]

As Filed with the Securities and Exchange Commission on March 4, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIAI HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 33-4103471 (I.R.S. Employer Identification Number) (214) 935-9853 (Address, ...

Core Viewpoint - NetraMark Holdings Inc. successfully closed the second tranche of its non-brokered private placement, raising a total of $3.5 million through the issuance of 3.5 million units at $1.00 per unit, with plans to use the proceeds for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The second tranche involved the issuance of 390,000 units at a price of $1.00 per unit, resulting in gross proceeds of $390,000 [1]. - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of an additional common share at an exercise price of $1.35 for two years [2]. - The total number of common shares outstanding after the second tranche is 92,223,699 [4]. Group 2: Regulatory and Insider Participation - The securities issued are subject to a four-month hold period, expiring on June 19, 2026, in accordance with Canadian securities laws [3]. - An insider participated in the second tranche, subscribing for 232,500 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the transaction's size relative to its market capitalization [5]. Group 3: Company Overview and Technology - NetraMark is focused on developing AI and machine learning solutions for the pharmaceutical industry, utilizing a unique topology-based algorithm to analyze patient data [8][9]. - The company's technology allows for the segmentation of small datasets into explainable and unexplainable subsets, enhancing the accuracy of clinical trial insights [7].

Core Viewpoint - NetraMark Holdings Inc. is uplisting to the Toronto Stock Exchange (TSX) from the Canadian Securities Exchange (CSE), which is expected to enhance its access to institutional investors and raise its profile in the capital markets [1][4]. Group 1: Uplisting Details - The common shares of NetraMark will be voluntarily delisted from the CSE effective February 17, 2026, and will commence trading on the TSX under the symbol "AIAI" on February 18, 2026 [1][2]. - The company will remain a "reporting issuer" under applicable Canadian securities laws during the transition from CSE to TSX [2]. Group 2: Company Strategy and Technology - The uplisting is seen as a significant milestone that reflects NetraMark's operational development and strengthens its positioning within capital markets as it advances the commercial adoption of its AI-powered platform, NetraAI [3][4]. - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, potentially increasing the likelihood of clinical trial success by avoiding overfitting [5]. - The company focuses on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to accurately segment diseases and classify patients [6].

Core Viewpoint - NetraMark Holdings Inc. has announced the appointment of Lawrence Guy to its Board of Directors, enhancing the Board's expertise in capital markets and investment management [1][2]. Group 1: Board Appointment - Lawrence Guy's appointment is expected to strengthen the Board with his extensive experience in capital markets, investment management, and public-company governance [2]. - Mr. Guy is currently a Managing Director at Next Edge Capital, focusing on strategic partnerships and evaluating new investment opportunities [2]. - His previous roles include Vice President at Purpose Investments and Portfolio Manager at Aston Hill Financial Inc., showcasing a strong background in financial leadership and corporate development [3]. Group 2: Educational Background and Current Roles - Mr. Guy holds a BA in Economics from the University of Western Ontario and is a Chartered Financial Analyst [4]. - He currently serves as a director for several companies, including Emerita Resources Corp., Lithium Ionic Corp., Nobel Resources Corp., and Halcones Precious Metals Corp. [4]. Group 3: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry [5]. - The company's innovative topology-based algorithm allows for the parsing of patient data into relevant subsets, enabling accurate disease segmentation and patient classification for drug sensitivity and treatment efficacy [5].

Core Viewpoint - NetraMark Holdings Inc. has successfully closed the first tranche of a non-brokered private placement, raising gross proceeds of $3,110,000, which will be utilized for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The first tranche involved the issuance of 3,110,000 units at a price of $1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional common share at an exercise price of $1.35 for a period of two years from the closing date [2]. - The securities issued are subject to a hold period expiring on May 28, 2026, as per applicable securities laws [3]. Group 2: Future Tranche and Financial Commitments - The company has received commitments for the second and final tranche of the private placement, expected to close soon for additional gross proceeds of $390,000 [4]. - Following the first tranche, there are now 91,778,520 common shares of NetraMark issued and outstanding [3]. Group 3: Insider Participation - Certain insiders participated in the first tranche, subscribing for a total of 2,060,000 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the nature of the transaction and its market capitalization [5]. Group 4: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [8]. - The company's AI technology, NetraAI, is designed to improve clinical trial success rates by effectively segmenting patient data into explainable and unexplainable subsets, addressing issues of overfitting common in other AI methods [7].

As Filed with the Securities and Exchange Commission on January 26, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIAI HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 33-4103471 (I.R.S. Employer Identification Number) 17304 Preston Road, Suite 520 Dallas, TX ...